Previous 10 | Next 10 |
Orgenesis (NASDAQ:ORGS): Q2 GAAP EPS of -$0.11 beats by $0.12. Revenue of $10.54M (+502.3% Y/Y) beats by $7.24M. Shares +3.73% PM. Press Release For further details see: Orgenesis EPS beats by $0.12, beats on revenue
GERMANTOWN, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today reported financial results for the second...
GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a co...
FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on schedule Licensing partner, Okogen, Inc., presented positive interim phase 2 clinical trial results of OKG-0301 (Ranpirnase) in acute adenoviral conjunctivitis GERMANTOWN,...
GERMANTOWN, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announces that enrollment has commenced fo...
GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting...
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Summer Solstice - Best Ideas fro...
Orgenesis is a mispriced and misunderstood biotechnology with a pipeline of over 30 licensed gene and cell therapies and a platform called Orgenesis Mobile Processing Labs. Due to reinvestment plans and two one-off expenses, the financials looked terrible on a superficial level. This ...
Orgenesis Inc. (ORGS) Q1 2021 Earnings Conference Call May 07, 2021 08:30 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Kelvin Se...
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...